Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

Sharp, A
Welti, J
Blagg, J
de Bono, JS

Open PDF

Open link

Publication date

September 2016

DOI

10.1158/1078-0432.ccr-16-1137

Publisher

American Association for Cancer Research (AACR)

Journal

Clinical Cancer Research

Abstract

Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466

Extracted data

We use cookies to provide a better user experience.

Data Protection

Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

Abstract

Extracted data

Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

Abstract

Extracted data

Related items

Related items